What is the recommended treatment for typhoid fever in an otherwise healthy adult?

Typhoid Fever Treatment

For an otherwise healthy adult with typhoid fever, azithromycin or a third-generation cephalosporin (ceftriaxone) should be the first-line treatment, with the choice guided by local resistance patterns and severity of illness.

Treatment Algorithm Based on Resistance Patterns

The selection of antibiotics for typhoid fever must be tailored to the known or suspected resistance profile of Salmonella typhi in your region:

For Fully Susceptible Strains

• Fluoroquinolones (ciprofloxacin, ofloxacin, gatifloxacin) remain effective when susceptibility is confirmed 1
• However, this scenario is increasingly rare in endemic regions

For Quinolone-Resistant or Nalidixic Acid-Resistant Strains (Most Common)

• First choice: Azithromycin 1

  • Superior outcomes compared to fluoroquinolones in resistant strains
  • Lower clinical failure rates (OR 0.48) and shorter hospital stays compared to fluoroquinolones 1
  • Significantly lower relapse rates (OR 0.09) compared to ceftriaxone 1

• Alternative: Ceftriaxone (third-generation cephalosporin) 1

  • Particularly effective for culture-confirmed cases
  • In one RCT, ceftriaxone showed lower failure rates (HR 0.24) in culture-confirmed populations 1

For Multidrug-Resistant (MDR) Strains

• Fluoroquinolone or cefixime if susceptible 1
• Azithromycin as alternative 1

For Extensively Drug-Resistant (XDR) Strains

• This emerging threat (particularly from Pakistan since 2016) responds to only limited antibiotics 2
• Requires susceptibility-guided therapy with carbapenems (meropenem) or azithromycin 3

Key Evidence Supporting Azithromycin Priority

The most compelling research evidence shows azithromycin demonstrates:

• Lower clinical failure rates than fluoroquinolones in areas with decreased ciprofloxacin susceptibility 1
• Reduced relapse rates compared to both fluoroquinolones and ceftriaxone 1
• Shorter hospital stays (approximately 1 day shorter) 1
• Effectiveness in children and adults across multiple trials 4

Critical Pitfalls to Avoid

Fluoroquinolone Trap: Despite in vitro disc sensitivity, fluoroquinolones often show poor clinical response in regions with nalidixic acid resistance 5. A trial was stopped early due to emergence of high-level ciprofloxacin and gatifloxacin resistance 1. Do not rely on fluoroquinolones as first-line in endemic areas without confirmed full susceptibility.

Older Antibiotics: Chloramphenicol, ampicillin, and trimethoprim-sulfamethoxazole show higher clinical failure rates than modern options and should be avoided unless susceptibility is confirmed and alternatives unavailable 1, 4

Cephalosporin Resistance: Emerging resistance to third-generation cephalosporins is documented 3. Always obtain blood cultures before treatment and adjust based on susceptibility results.

Practical Clinical Approach

1. Obtain blood cultures immediately before starting antibiotics
2. Start empiric treatment based on:
   • Travel history (South Asia = high resistance probability)
   • Local epidemiology
   • Severity of illness
3. Preferred empiric regimen: Azithromycin (oral if tolerated) or ceftriaxone (IV if severely ill)
4. Adjust therapy once susceptibilities return
5. Monitor for complications: confusion, bleeding, intestinal perforation, bone infection
6. Duration: Typically 5-7 days for azithromycin; 10-14 days for other agents

The evidence strongly favors moving away from fluoroquinolones as empiric first-line therapy given widespread resistance patterns, with azithromycin emerging as the most effective option balancing efficacy, safety, and resistance patterns 4.